| Masked chimeric antigen receptor for tumor-specific activation X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang Molecular Therapy 25 (1), 274-284, 2017 | 98 | 2017 |
| Nanogel-integrated pH-responsive composite hydrogels for controlled drug delivery GE Cinay, P Erkoc, M Alipour, Y Hashimoto, Y Sasaki, K Akiyoshi, ... ACS Biomaterials Science & Engineering 3 (3), 370-380, 2017 | 92 | 2017 |
| Evaluating CAR‐T cell therapy in a hypoxic 3D tumor model Y Ando, EL Siegler, HP Ta, GE Cinay, H Zhou, KA Gorrell, H Au, ... Advanced healthcare materials 8 (5), 1900001, 2019 | 90 | 2019 |
| Adnectin-based design of chimeric antigen receptor for T cell engineering X Han, GE Cinay, Y Zhao, Y Guo, X Zhang, P Wang Molecular Therapy 25 (11), 2466-2476, 2017 | 65 | 2017 |
| Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy X Chen, S Yang, S Li, Y Qu, HY Wang, J Liu, ZS Dunn, GE Cinay, ... Molecular Therapy-Oncolytics 21, 144-157, 2021 | 36 | 2021 |
| Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered T cells Y Qu, ZS Dunn, X Chen, M MacMullan, G Cinay, H Wang, J Liu, F Hu, ... Human Gene Therapy 33 (5-6), 223-236, 2022 | 21 | 2022 |
| Targeted drug delivery: overcoming barriers through the design of novel delivery vehicles P Erkoc, GE Cinay, S Kizilel Philippines: SM Group, 2015 | 5 | 2015 |
| Cell-based cancer immunotherapy using chimeric antigen receptor (CAR)-engineered natural killer (NK) cells surface-modified with drug-loaded nanoparticles targeting adenosine … GE Cinay The Journal of Immunology 204 (1_Supplement), 170.10-170.10, 2020 | 1 | 2020 |
| Engineering CAR-expressing natural killer cells with cytokine signaling and synthetic switch for an off-the-shelf cell-based cancer immunotherapy Y Qu, E Siegler, C Cheng, J Liu, G Cinay, N Bagrodia, P Wang MRS Communications 9 (2), 433-440, 2019 | 1 | 2019 |
| Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy ZS Dunn, Y Qu, M MacMullan, X Chen, G Cinay, P Wang Human Gene Therapy 34 (21-22), 1145-1161, 2023 | | 2023 |
| Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates CAR T cell solid tumor efficacy. Z Dunn, Y Qu, M MacMullan, X Chen, G Cinay, P Wang Human Gene Therapy, 2023 | | 2023 |
| 111 Armored CAR T cells secreting 4–1BB ligand crosslinked to PD-1 checkpoint inhibitor for enhanced solid tumor efficacy Z Dunn, Y Qu, M MacMullan, X Chen, G Cinay, P Wang Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
XIAOLU HANAbbvie IncDirección de correo verificada de abbvie.com
